Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 5, 2006, Pages 1036-1043

  Braithwaite, Ronald S ^a   Shechter, S ^b   Roberts, M S ^b,c   Schaefer, A ^b,c   Bangsberg, D R ^d   Harrigan, P R ^e   Justice, A C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Pittsburgh   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

AIDS; Effectiveness; Efficacy; HAART

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; COHORT ANALYSIS; COMPUTER SIMULATION; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; VIROLOGY;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; COMPUTER SIMULATION; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HUMANS; MUTATION; PATIENT COMPLIANCE;

EID: 34249319607     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl386     Document Type: Article

References (21)

1. Palella FJ,Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
2. Karon JM, Fleming PL, Steketee RW et al. HIV in the United States at the turn of the century: An epidemic in transition. Am J Public Health 2001; 91: 1060-8.
3. Phillips AN, Pradier C, Lazzarin A et al. Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. AIDS 2001; 15: 2385-95.
4. Paris D, Ledergerber B, Weber R et al. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. AIDS Res Hum Retroviruses 1999; 15: 1631-8.
5. Friedland GH, Williams A. Attaining higher goals in HIV treatment: The central importance of adherence. AIDS 1999; 13: S61-72.
6. Bangsberg DR, Porco TC, Kagay C et al. Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates. J Infect Dis 2004; 190: 162-5.
7. Paterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30.
8. Bangsberg DR, Charlebois ED, Grant RM et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 2003; 17: 1925-32.
9. Harrigan PR, Hogg RS, Dong WW et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191: 339-47.
10. Braithwaite RS, Justice AC, Chang CC et al. Estimating the proportion of patients infected with HIV who will die of comorbid diseases. Am J Med 2005; 118: 890-8.
11. Braithwaite RS, Schechter S, Chung C et al. Estimating the rate of accumulating drug resistance mutations in the HIV genome. Value Health 2006; in press.
12. Choo PW, Rand CS, Inui TS et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999; 37: 846-57.
13. Liu H, Golin CE, Miller LG et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001; 134: 968-77.
14. Bangsberg DR, Acosta EP, Gupta R et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006; 20: 223-31.
15. Sethi AK, Celentano DD, Gange SJ et al. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003; 37: 1112-18.
16. Roge BT, Barfod TS, Kirk O et al. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: Analysis of failure rates in a randomized study. HIV Med 2004; 5: 344-51.
17. de la Rosa R, Ruiz-Mateos E, Rubio A et al. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy. J Antimicrob Chemother 2004; 53: 95-101.
18. Bangsberg DR., Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother 2004; 53: 696-9.
19. Wahl LM, Nowak MA. Adherence and drug resistance: Predictions for therapy outcome. Proc Biol Sci 2000; 267: 835-43.
20. Kagay CR, Porco TC, Liechty CA et al. Modeling the impact of modified directly observed antiretroviral therapy on HIV suppression and resistance, disease progression, and death. Clin Infect Dis 2004; 38: S414-20.
21. King MS, Brun SC, Kempf DJ. Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. J Infect Dis 2005; 191: 2046-52.